The demand for interventional
medical core products has increased continuously with the improvement of living
quality and the coming of aging society; PCI (percutaneous coronary
intervention) surgical cases also increased year by year. In 2012, the usage
quantity of coronary stent was about 633,600 sets and the market scale reached
CNY 3.15 billion in China.
To
Read the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/research-on-china-coronary-stent-industry-2013-2017
The overall market share of domestic
brands decreased to 65% in 2012 from 70% in 2011. However, the landscape of Top
3 enterprises was not changed; MicroPort still occupied the leading position
with 23% market shares, following by LePu and Shandong JW with 21% and 20%
market shares respectively.
In 2012, the major foreign brands
Boston Scientific, Medtronic and Abbott strengthened the marketing efforts, and
the market share of the three brands reached about 33% in China.
Huidian Research takes a view that,
from the aspects of market scale, the annual growth rate of stent system will
remain 8% globally on the whole. At present, cardiac interventional surgeries
in some developed countries, such as Europe, America, Japan, are comparative
mature, so the annual growth rate will continue to remain 3%-5%. While the
stent system market of emerging countries represented by China, the annual
growth rate will remain 10%-15% in the next five years, the usage quantity
(sale volume) of stent system will reach 1.299 million sets.
Contact
M/s Sheela
90 Sate Street, Suite
700
Albany, NY 12207
USA – Canada Toll
Free: 866-997-4948
No comments:
Post a Comment